October 29, 2026

Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

PPMX and Kyorin Pharmaceutical Enter into Joint Research Agreement to Create Novel Antibody Drugs

Perseus Proteomics Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Takuya Yokokawa; hereinafter "PPMX") and Kyorin Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Yutaka Ogihara) today announced that they have entered into a joint research agreement to develop novel therapeutics for a specific disease area. Under the agreement, the companies will leverage PPMX's proprietary antibody technologies to create new antibody-based drugs.

The impact of this agreement on the current fiscal year's financial results is expected to be immaterial.